Growth Hormone Releasing Peptides: Mechanisms and Current Research

Research into Growth Hormone Releasing Peptide Research examines a distinct group of synthetic growth hormone secretagogues that stimulate endogenous growth hormone (GH) release through the growth hormone secretagogue receptor rather than the classical growth hormone-releasing hormone receptor.

This distinction is important. GHRPs such as GHRP-6 and Ipamorelin are not the same as GHRH-derived peptides such as Sermorelin. Instead, GHRPs interact primarily with the ghrelin receptor, commonly called GHS-R1a, creating a second regulatory pathway within the hypothalamic-pituitary GH system. The receptor was identified before its natural ligand was known, and ghrelin was later discovered as its endogenous ligand in 1999. (Howard et al., 1996) (Kojima et al., 1999)

For researchers looking for peptide materials for laboratory investigation, visit the Nume Peptides to explore the available research peptide collection.

What Are Growth Hormone Releasing Peptides?

Growth hormone releasing peptides, or GHRPs, are synthetic peptides originally developed because of their ability to stimulate GH secretion. Despite their name, they do not simply mimic endogenous GHRH.GHRP-6 is one of the earliest extensively characterized compounds in this group. It is a synthetic hexapeptide that demonstrated GH-releasing activity in both experimental animals and humans. Later compounds were developed to modify potency, receptor selectivity, and endocrine effects.

GHRPs are part of the broader growth hormone secretagogue, or GHS, family. The discovery of their receptor helped establish that GH secretion is regulated through at least two major stimulatory systems:

• the hypothalamic GHRH–GHRH receptor pathway;
• the ghrelin/GHS-R1a pathway;
• interactions between these two systems;
• modulation by somatostatin;
• feedback from GH and IGF-1.

The natural ligand for GHS-R1a, ghrelin, is a 28-amino-acid peptide whose acylation at serine 3 is important for high-affinity receptor activity. Its discovery provided a physiological framework for understanding why synthetic GHRPs can stimulate GH secretion. (Kojima et al., 1999)

Explore research compounds studied for GH secretion, GHRH signaling, and secretagogue pathways in the Growth Hormone collection.

How Do Growth Hormone Releasing Peptides Interact With the Ghrelin Receptor?

GHS-R1a is a G-protein-coupled receptor expressed in regions including the pituitary and hypothalamus. It was cloned in 1996 during research into synthetic GH secretagogues. (Howard et al., 1996)

After ghrelin was identified as its endogenous ligand, the receptor became known as the ghrelin receptor. Synthetic compounds such as GHRP-6 and Ipamorelin can activate this signalling system without being structurally identical to ghrelin.

Intracellular signalling after receptor activation

GHS-R1a primarily couples to Gq-related signalling. Activation can trigger phospholipase C pathways, intracellular calcium mobilization, and other downstream signalling events involved in endocrine and metabolic responses. Reviews of ghrelin signalling also describe β-arrestin, DAG, and additional pathway interactions, emphasizing that GHS-R1a signalling is more complex than a single linear cascade. (Al Massadi et al., 2019)

In simplified form, experimental signalling may involve:

1. GHRP binding to GHS-R1a;
2. activation of G-protein signalling;
3. phospholipase C activity;
4. intracellular calcium changes;
5. stimulation of somatotroph activity;
6. increased GH release.

However, pituitary receptor activation is only part of the mechanism. GHRPs also interact functionally with hypothalamic GHRH and somatostatin systems.

How Are GHRPs Studied in Experimental Research?

Researchers use several approaches to investigate GHRPs because GH secretion is pulsatile and highly dependent on physiological context.

Pituitary and receptor models

Cell-based systems allow researchers to examine whether a GHRP directly activates GHS-R1a or stimulates GH release from pituitary cells. These studies can also compare receptor potency and selectivity. Human fetal pituitary cultures, for example, were shown to express functional GHRP receptors, and GHRP-6 increased GH secretion in a concentration-dependent manner. (Adams et al., 1998)

Human endocrine challenge studies

Human studies have historically examined GHRPs by measuring GH responses following experimental administration.

Common endpoints include:

• peak circulating GH;
• GH area under the curve;
• timing of GH release;
• interaction with GHRH;
• ACTH and cortisol responses;
• pharmacokinetic parameters;
• variability among participants.

A major finding from this research is that GHRP-mediated GH secretion depends substantially on the existing endocrine environment.

Interaction studies

GHRP-6 has often been studied together with GHRH because the two compounds activate different but interacting pathways. One human study found that combining GHRP-6 with GHRH produced a considerably larger GH response than either signal alone. (Peñalva et al., 1993)

This interaction is one reason Growth Hormone Releasing Peptide Research is particularly useful for investigating regulation of the hypothalamic-pituitary axis.

Explore research peptides with ≥99% HPLC-verified purity and batch-specific COA documentation – GHRP-6

Which Growth Hormone Releasing Peptides Are Commonly Investigated?

Among the many synthetic secretagogues developed experimentally, GHRP-6 and Ipamorelin provide useful examples of how compounds within the same broad class can produce different endocrine profiles.

GHRP-6

GHRP-6 is a synthetic hexapeptide and one of the foundational research compounds in the GHRP field.

It has been investigated for:

• direct stimulation of GH secretion;
• interaction with endogenous GHRH;
• interaction with somatostatin tone;
• combined GHRH/GHRP responses;
• assessment of pituitary GH reserve.

Although early models sometimes proposed relatively independent GHRP activity, later human experiments showed that endogenous GHRH contributes strongly to maximal GHRP-6 responses.

In nine healthy men, blocking GHRH activity eliminated most of the GH response to GHRP-6, supporting an important interaction between endogenous hypothalamic GHRH and the GHRP pathway. (Mallo et al., 1998)

Ipamorelin

Ipamorelin is a synthetic pentapeptide developed as a more selective GH secretagogue. In early experimental studies, Ipamorelin stimulated GH release while showing greater selectivity for GH than earlier compounds such as GHRP-6 and GHRP-2. Under the tested conditions, it produced less ACTH and cortisol stimulation than those comparators. (Raun et al., 1998)

Human pharmacokinetic and pharmacodynamic research later confirmed episodic GH release following Ipamorelin exposure. In healthy volunteers, GH concentrations rose to a peak and subsequently declined, while considerable variability in pharmacodynamic responses was observed between individuals. (Gobburu et al., 1999)

Researchers should compare defined molecular sequences rather than assuming that all compounds labelled as GH secretagogues have equivalent pharmacology.

What Does Current Evidence Show About GHRP Signaling?

The strongest evidence from GHRP research supports three interconnected conclusions.

GHS-R1a is distinct from the GHRH receptor

The discovery of GHS-R established a GH-regulatory pathway distinct from classical GHRH signalling. The later identification of ghrelin as its endogenous ligand confirmed that this receptor belongs to a physiological signalling system rather than being only a target for synthetic compounds. (Kojima et al., 2001)

GHRP signalling depends on the broader GH regulatory network

GHRPs may activate their own receptor pathway, but GH release cannot be interpreted without considering endogenous GHRH and somatostatin.

Experimental findings have shown that:

• GHRP-6 alone can stimulate GH;
• GHRH alone can stimulate GH;
• combined signalling can produce much larger responses;
• blocking endogenous GHRH can markedly reduce GHRP-6 responses;
• physiological state can change the magnitude of GH release.

This explains why receptor activation and circulating GH response are related but not identical experimental endpoints.

GHRPs have different endocrine selectivity

Ipamorelin and GHRP-6 should not be treated as interchangeable. Early comparative work indicates that Ipamorelin was more selective for GH, while older GHRPs could influence additional pituitary-adrenal hormones under some experimental conditions. (Raun et al., 1998)

Researchers should therefore consider:

• receptor pharmacology;
• GH response;
• ACTH and cortisol responses;
• interaction with GHRH;
• individual physiological variability;
• duration of peptide exposure.

An increase in experimentally measured GH should also not be converted automatically into claims about muscle growth, anti-aging, fat loss, recovery, or another downstream clinical effect.

Canadian research context

Health Canada has taken enforcement action against unauthorized injectable peptide products labelled as both GHRP-6 and Ipamorelin. A 2025 public advisory specifically listed GHRP-6 and Ipamorelin among unauthorized products seized in Canada, while Health Canada’s April 2026 advisory again listed Ipamorelin among examples of unauthorized injectable peptide products. (Health Canada, 2025) (Health Canada, 2026)

These regulatory actions concern unauthorized products and should remain separate from laboratory investigation of GHRP signalling.

Discover research peptides with ≥99% HPLC-verified purity and batch-specific COA documentation – Ipamorelin (10 mg).

FAQs About Growth Hormone Releasing Peptides

Are GHRPs the Same as GHRH?

No. GHRPs primarily interact with the ghrelin/GHS-R1a system, whereas GHRH acts through the GHRH receptor.

What Receptor Does GHRP-6 Target?

GHRP-6 belongs to the growth hormone secretagogue class associated with GHS-R1a, also known as the ghrelin receptor.

Is Ghrelin a GHRP?

Ghrelin is the endogenous ligand for GHS-R1a. Synthetic GHRPs were developed before ghrelin was identified, but both can activate the same receptor system.

How Does Ipamorelin Differ From GHRP-6?

Ipamorelin was developed as a more selective GH secretagogue. Experimental comparisons found greater GH selectivity and less ACTH/cortisol stimulation than GHRP-6 under the conditions studied.

Does GHRP-6 Require GHRH to Work?

GHRP-6 can directly stimulate GH-related pathways, but human studies show that endogenous GHRH contributes substantially to achieving a maximal GH response. (Mallo et al., 1998)

Does Higher GH Prove a Broader Physiological Benefit?

No. A measured GH response is an endocrine endpoint. It does not independently demonstrate downstream effects such as changes in body composition, recovery, or aging.

Conclusion

Growth Hormone Releasing Peptide Research has helped define a GH-regulatory system distinct from the traditional GHRH pathway. The discovery of GHS-R1a and its endogenous ligand ghrelin demonstrated that synthetic GHRPs were acting on a physiologically relevant receptor network. GHRP-6 remains one of the most extensively investigated early secretagogues and illustrates the interaction between GHS-R signalling, endogenous GHRH, and somatostatin. Ipamorelin represents a later generation of GHRP research focused on greater endocrine selectivity.

The most accurate interpretation therefore separates receptor activation from circulating GH response and both from downstream physiological or clinical outcomes.

For researchers looking for peptide materials for laboratory investigation, visit the Nume Peptides to explore the available research peptide collection.

Disclaimer: This content is provided for educational and scientific research purposes only. Research peptides are intended for laboratory research only and are not intended for human consumption or medical use.